DEVELOPMENT AND VALIDATION OF DAPAGLIFLOZIN BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD AND IT'S FORCED DEGRADATION STUDIES

SHAKIR  BASHA S; Sravanthi P

doi:10.22159/ajpcr.2017.v10i11.19705

Authors

SHAKIR BASHA S Department of Pharmaceutical Analysis, Sree Vidyanikethan College of Pharmacy, Tirupati, Andhra Pradesh, India
Sravanthi P Department of Pharmacology, Sree Vidyanikethan College of Pharmacy, Tirupathi, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i11.19705

Keywords:

Dapagliflozin, High-performance liquid chromatography, System suitability, Repeatability, Purity threshold

Abstract

Â

Â Objective: To develop and validate a simple, selective, precise, and accurate method for the estimation of dapagliflozin using reversed-phase high-performance liquid chromatography (RP-HPLC) technique in bulk and tablet formulation.

Methods: The proposed method utilizes chromatographic conditions hypersil BDS (250 mm Ã— 4.6 mm, 5 Î¼), mobile phase was buffer:acetonitrile (60:40) ratio, flow rate was maintained 1 ml/minute, column temperature was set at 30Â°C, detection wave length was 245 nm, and diluent was mobile phase.

Results: By injecting 5 times of the standard solution system suitability parameters were studied, and results were found well under the acceptance criteria. The linearity study was performed by taking 25-150% levels, and the R2 value was found to be 0.999, precision was found to be 0.5 for repeatability and 0.31 for intermediate precision. The % recovery was found to be 99.89%. Limit of detection and limit of quantitation were found to be 0.60 Î¼g/ml and 1.81 Î¼g/ml, respectively. The % purity was found to be 99.71%. Degradation study on dapagliflozin was performed and concluded that the purity threshold was more than purity angle and within the acceptable range.

Conclusion: The developed RP-HPLC method for dapagliflozin was found to be simple, precise, accurate, reproducible, and cost effective. Statistical analysis of the developed method conforms that the proposed method is an appropriate and it can be useful for the routine analysis. This method gives the basic idea to the researcher who is working in area such as product development and finish product testing.

Downloads

Download data is not yet available.

References

List FJ, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose co-transport inhibition with dapagliflozin in Type 2 diabetes. Diabetes care 2009;32(4):650-7.

Aubry AF, Gu H, Magnier R, Morgan L, Xu X, Tirmenstein M, et al. Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis 2010;2(12):2001-9.

Yunoos M, Sankar DG. A validated stability indicating high-performance liquid chromatographic method for simultaneous determination of metformin HCL and dapagliflozin in bulk drug and tablet dosage form. Asian J Pharm Clin Res 2015;8(3):0974-2441.

Gaware D, Patil RN, Harole M. A validated stability indicating RP-HPLC method for simultaneous determination of metformin and canagliflozinin pharmaceutical formulation. World J Pharm Pharm Sci 2015;4(12):631-40.

Bhoomaiah B, Shree AJ. Development and validation of RP-HPLC method for simultaneous determination of metformin and miglitol in bulk and pharmaceutical formulation. Int J Pharm Pharm Sci 2014;6(6):0975-1491.

Manasa S, Dhanalakshmi K, Reddy GN, Sreenivasa S. Method development and validation of dapagliflozin in API by RPHPLC and UV-spectroscopy. Int J Pharm Sci Drug Res 2014;6(3):250-2.

Jani BR, Shah KV, Kapupara PP. Development and validation of UV spectroscopic method for simultaneous estimation of dapagliflozin and metformin hydrochloride in synthetic mixture. Int J Res Dev Pharm Life Sci 2015;4(3):1569-76.

Jani BR, Shah KV, Kapupara PP. Development and validation of UV spectroscopic first derivative method for simultaneous estimation of dapagliflozin and metformin hydrochloride in synthetic mixture. J Bioequiv Stud 2015;1(1):102.

van der Walt JS, Hong Y, Zhang L, Pfister M, Boulton DW, Karlsson MO. A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment. CPT Pharmacometrics Syst Pharmacol 2013;2:e42.

Tatarkiewicz K1, Polizzi C, Villescaz C, Dâ€™Souza LJ, Wang Y, Janssen S, et al. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. Diabetes Obes and Metab 2014;16(4):376-80.

Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with Type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85(4):962-71.

Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of Type 2 diabetes mellitus. Diabetes Ther 2014;5(1):73-96.

Jadoon K, Idris I. Dapagliflozin: A once-daily oral therapy sodium-glucose cotransporter-2 inhibitor for the treatment of adult patients with Type 2 diabetes. Clinical medicine insights: Therapeutics 2011;3:185-94.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with Type 2 diabetes. Diabetes Obes Metab 2013;15(9):853-62.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in Type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33(10):2217-24.

Jayaprakash R, Natesan SK. Stability indicating RP-HPLC method development and validation for the simultaneous determination of Vildaglipin and Metformin in pharmaceutical dosage form. Int J Pharm Pharm Sci 2017;9(3):150-7.

Dasgupta S, Dey S, Pal P, Mazumder B. RP-HPLC method development, validation, and quantification of Lornoxicam in lipid nanoparticle formulations. Int J Pharm Pharm Sci 2016;8(11):152-8.